Prasugrel, a novel third-generation thienopyridine, is the latest option available for management of ACS patients undergoing PCI. TRITON-TIMI 38, the main trial with prasugrel, along with its sub-studies have established the role of the drug as a more potent, faster, consistent and superior agent than clopidogrel, which is the current standard of care. It can also prove to be a favourable option in patients with STEMI or diabetes. This slide set gives an overall information on pharmacology, efficacy, dosage and administration, and place in therapy of this latest antiplatelet agent.